Gynecare Interceed

In your care, she is protected...
...for all her tomorrows

The adhesion barrier that conforms for control you can count on

**GYNECARE INTERCEED® Absorbable Adhesion Barrier**

*is easy to handle, and conforms to pelvic organs*

- Does not crack, tear, or stick to gloves
- May be rolled or folded to aid in placement. Final placement should be flat (not folded or rolled)
- Pliability allows it to contour to organs of varying shapes and sizes for full coverage

**Easy to use right out of the box**

- Must be applied dry to traumatized tissues, after meticulous hemostasis has been achieved\(^1\)
- Forms a continuous protective coating during the critical 5-7 day peritoneal healing period\(^2\)
Proven safe and effective in gynecologic procedures

GYNECARE INTERCEED Adhesion Barrier has been shown in various gynecologic studies to:
• Significantly and safely reduce the incidence of both new and reformed adhesions\textsuperscript{3,4}
• Be clinically effective across multiple gynecological procedures\textsuperscript{3}
• Be up to 2 times more effective than good surgical technique alone in achieving an adhesion-free outcome\textsuperscript{5}

Percent of adhesion-free outcomes\textsuperscript{6-9}

- Reproductive surgery in infertile women\textsuperscript{6}: 63%
- Adhesiolysis\textsuperscript{6}: 51%
- Surgical treatments of endometriosis\textsuperscript{5}: 50%
- Ovarian surgery\textsuperscript{7}: 47%
- Tubal surgery\textsuperscript{7}: 50%
- Fimbria surgery\textsuperscript{7}: 58%

0 14% 24% 26% 24% 38%

- Patients with GYNECARE INTERCEED Adhesion Barrier
- Patients without GYNECARE INTERCEED Adhesion Barrier

© 2016 Ethicon US, LLC. All rights reserved.
Choose the adhesion barrier that matters

Ordering information
For more information or to order product, contact your Ethicon representative for GYNECARE INTERCEED® Absorbable Adhesion Barrier.

<table>
<thead>
<tr>
<th>Product</th>
<th>Ordering Code</th>
<th>How Supplied</th>
</tr>
</thead>
<tbody>
<tr>
<td>GYNECARE INTERCEED</td>
<td>4350</td>
<td>10 sheets per box</td>
</tr>
<tr>
<td>Adhesion Barrier</td>
<td></td>
<td>3 in x 4 in</td>
</tr>
<tr>
<td>3x4</td>
<td></td>
<td>76 cm x 10.2 cm</td>
</tr>
<tr>
<td>GYNECARE INTERCEED</td>
<td>4350XL</td>
<td>10 sheets per box</td>
</tr>
<tr>
<td>Adhesion Barrier</td>
<td></td>
<td>5 in x 6 in</td>
</tr>
<tr>
<td>5x6</td>
<td></td>
<td>12.7 cm x 15.2 cm</td>
</tr>
</tbody>
</table>

Essential product information

Indications:
GYNECARE INTERCEED Adhesion Barrier is indicated as an adjuvant in open (laparotomy) gynecologic pelvic surgery for reducing the incidence of postoperative pelvic adhesions after meticulous hemostasis is achieved consistent with microsurgical principles.

Contraindications:
The use of GYNECARE INTERCEED Adhesion Barrier is contraindicated in the presence of frank infection. GYNECARE INTERCEED Adhesion Barrier is not indicated as a hemostatic agent. Appropriate means of achieving hemostasis must be employed.

Warnings:
The safety and effectiveness of GYNECARE INTERCEED Adhesion Barrier in laparoscopic surgery or any procedures other than open (laparotomy) gynecologic microsurgical procedures have not been established.

Postoperative adhesions may be induced by GYNECARE INTERCEED Adhesion Barrier application if adjacent tissues (eg, ovary and tube) and structures are coated or conjoined by the device, or if GYNECARE INTERCEED Adhesion Barrier is folded, wadded or layered. Care must be taken to apply GYNECARE INTERCEED Adhesion Barrier in single layers, interposed between adjacent anatomic structures at risk for adhesion formation.

GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized.

Foreign body reactions may occur in some patients.

Interactions may occur between GYNECARE INTERCEED Adhesion Barrier and some drugs used at the surgical site.

Adverse reactions:
The type and frequency of adverse events reported are consistent with events typically seen following surgery. Postoperative adhesions may occur in the presence of GYNECARE INTERCEED Adhesion Barrier.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

References:

The safety and effectiveness of using GYNECARE INTERCEED Adhesion Barrier in combination with other adhesion prevention treatments have not been clinically established.

GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized.

Ectopic pregnancies have been associated with fertility surgery of the female reproductive tract. No data exist to establish the effect, if any, of GYNECARE INTERCEED Adhesion Barrier on the occurrence of ectopic pregnancies. No adequate studies have been conducted in women who have become pregnant within the first month after exposure to GYNECARE INTERCEED Adhesion Barrier. No teratogenic studies have been performed. Therefore, avoidance of conception should be considered during the first complete menstrual cycle after use of GYNECARE INTERCEED Adhesion Barrier. The safety and effectiveness of using GYNECARE INTERCEED Adhesion Barrier in combination with other adhesion prevention treatments have not been clinically established.

GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized.

Adverse reactions:
The type and frequency of adverse events reported are consistent with events typically seen following surgery. Postoperative adhesions may occur in the presence of GYNECARE INTERCEED Adhesion Barrier.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

References:

The safety and effectiveness of using GYNECARE INTERCEED Adhesion Barrier in combination with other adhesion prevention treatments have not been clinically established.

GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized.

Ectopic pregnancies have been associated with fertility surgery of the female reproductive tract. No data exist to establish the effect, if any, of GYNECARE INTERCEED Adhesion Barrier on the occurrence of ectopic pregnancies. No adequate studies have been conducted in women who have become pregnant within the first month after exposure to GYNECARE INTERCEED Adhesion Barrier. No teratogenic studies have been performed. Therefore, avoidance of conception should be considered during the first complete menstrual cycle after use of GYNECARE INTERCEED Adhesion Barrier. The safety and effectiveness of using GYNECARE INTERCEED Adhesion Barrier in combination with other adhesion prevention treatments have not been clinically established.

GYNECARE INTERCEED Adhesion Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, GYNECARE INTERCEED Adhesion Barrier must not be resterilized.